Gestational diabetes mellitus (GDM) is the most common metabolic disease of pregnancy, associated with several perinatal complications. Adequate glycemic control has been proved to decrease risk of GDM-related complications. Several studies have shown the beneficial effect of exercise and medical nutrition treatment on glycemic and weight control in GDM-affected women. Moreover, pharmacological agents, such as insulin and specific oral anti-diabetic agents can be prescribed safely during pregnancy, decreasing maternal blood glucose and, thus, perinatal adverse outcomes. Multi-disciplinary treatment approaches that include both lifestyle modifications (medical nutritional therapy and daily physical exercise) and pharmacological treatment, in cases of failure of the former, constitute the most effective approach. Insulin is the gold standard pharmacological agent for GDM treatment. Metformin and glyburide are two oral anti-diabetic agents that could serve as alternative, although not equal in terms of effectiveness and safety, treatment for GDM. As studies on short-term safety of metformin are reassuring, in some countries it is considered as first-line treatment for GDM management. More studies are needed to investigate the long-term effects on offspring. As safety issues have been raised on the use of glyburide during pregnancy, it must be used only when benefits surpass possible risks.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.metabol.2018.03.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is there a risk of developmental problems in infants born to mothers with gestational diabetes mellitus and/or pre-eclampsia?
PLoS One
January 2025
Developmental and Early Physiotherapy Unit, Faculty of Physical Therapy and Rehabilitation, Hacettepe University, Ankara, Türkiye.
Objective: The aims of this study were (i) to describe the early spontaneous movements in 3-to 5-month-old infants in groups of infants born to mothers with GDM and/or PE, (ii) to compare them, and (iii) to analyze the differences between infants with these risk factors and typically developing infants born to mothers without GDM and/or PE and other risk factors.
Methods: This cohort study included 255 infants in 4 groups: (i) 96 infants born to mothers with GDM, (ii) 78 infants born to mothers with PE, (iii) 31 infants born to mothers with GDM and PE, and (iv) 50 typically developing infants. Early spontaneous movements, including not only fidgety movements but also concurrent movement and postural patterns, were assessed using the General Movements Assessment (GMA), which determines the Motor Optimality Score-Revised (MOS-R).
Association of Influenza Vaccination During Pregnancy with Health Outcomes in Mothers and Children: A Population-Based Cohort Study.
Clin Pharmacol Ther
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
Immunization rates of maternal influenza vaccination during pregnancy remain suboptimal, with concerns about potential harm to the mothers and their offspring. We conducted a population-based cohort study, using mother-child linked database in Korea: (a) maternal cohort between December 2019, and March 2022; (b) neonatal cohort between September 2020, and June 2021. Exposure was defined as influenza vaccination during pregnancy.
View Article and Find Full Text PDFAGDMP1 alleviates insulin resistance by modulating heat shock protein 60-mediated IRS-1/AKT/GLUT4 pathway and adipose inflammation: A potential therapeutic peptide for gestational diabetes mellitus.
FASEB J
January 2025
Changzhou Maternal and Child Health Care Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, China.
Gestational Diabetes Mellitus (GDM) is the most frequent complication during pregnancy. Pharmacological interventions, such as peptide drugs that focused on improving the insulin sensitivity might be promising in the prevention and treatment of GDM. In this study, we aimed to investigate the role and mechanism of a novel peptide, named AGDMP1 (Anti-GDM peptide 1), which we previously identified lower in the serum of GDM patients using mass spectrometry, on the adipose insulin resistance in GDM.
View Article and Find Full Text PDFHybrid remote and in-clinic maternal-fetal surveillance for women with gestational diabetes: A prospective pilot study.
Int J Gynaecol Obstet
January 2025
The Josef Buchmann Gynecology and Maternity Center, Sheba Medical Center, Tel Hashomer, Israel.
Objective: This study explores a hybrid approach to maternal-fetal care for gestational diabetes (GD), integrating virtual visits seamlessly with in-clinic assessments. We assessed the feasibility, time efficiency, patient satisfaction, and clinical outcomes to facilitate wider adoption of maternal-fetal telemedicine.
Methods: We conducted a 4-week prospective study involving 20 women with GD at ≥32 weeks of pregnancy, alternating between remote and in-clinic weekly visits.
Reduced fetal ductus venosus shunt fraction is associated with adverse perinatal outcomes in pregnancy with pregestational diabetes mellitus.
Arch Gynecol Obstet
January 2025
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductive Medicine, 3 Mendeleyevskaya Line, St. Petersburg, 199034, Russia.
Purpose: We aimed to determine fetal liver perfusion in PGDM and GDM pregnancies and to assess the relation of ductus venosus (DV) shunt fraction with adverse pregnancy outcomes.
Methods: We conducted a prospective longitudinal observational study including 188 pregnant women: group I-patients with pregestational DM (PGDM, n = 86), group II-patients with gestational DM (GDM, n = 44), group III-control (n = 58). The patients included in the study underwent ultrasound examination at 30-40 weeks of pregnancy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!